spacer
home > ebr > spring 2002 > editor's letter
PUBLICATIONS
European Biopharmaceutical Review

Editor's Letter

"To merge or not to merge?" That does indeed seem to be a pertinent question, given the capital market conditions in Europe and elsewhere in the biotech business at present. And it's been like that for some time now if one compares the number of IPOs in Europe in 2001 (four compared with approximately 40 the year before). Although 2000 was clearly an exceptional year in the life science business, prospects for a listing remain poor today - on whichever side of the Atlantic you happen to be sitting. Given this reality, consolidation seems not only logical, but essential for the survival and growth of European life science companies. Is consolidation happening? There is some evidence to suggest that it is in the US, according to the article from Neal Ransome, European Leader of PricewaterhouseCoopers' Healthcare Corporate Finance Team. However, it seems that the trend is being driven by 'big biotech' companies (more akin to big pharma), rather than by small and medium biotech.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PharmaFluidics awarded VLAIO research grant

Ghent, Belgium – June 2, 2020 PharmaFluidics NV, innovative player in the field of analytical chromatography with its unique high-resolution µPAC™ micro-Chip technology, announces that it has been awarded a € 613 k grant from Flanders’ Innovation & Entrepreneurship Agency (VLAIO). The grant will run over two years and will support the further optimization of PharmaFluidics’ manufacturing flow, and to develop complementary new surface-modified µPAC™ products.
More info >>

White Papers

Clinical Trial Site Contracting: The Conservative, Progressive and Hybrid Models

DrugDev

For the last 20 years, pharmaceutical companies have turned to a variety of clinical outsourcing solutions to reduce costs and improve timelines, enabling them to focus on their core value of research and development. In today’s tightly competitive market, companies are constantly striving for ways to further cut costs and reduce study startup cycle times, while maintaining quality. One of the key cost factors in global R&D spending, estimated at around $102 billion per Kalorama market research, is the cost of conducting clinical trials. CRO’s, which account for about 30% of the total R&D spending, have risen to the challenge of the clinical, technical and administrative management of these trials. But some pharmaceutical companies question how much control to relinquish to vendor partners, especially in the legal arena, due to potential ramifications.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement